Dana-Farber Cancer Institute

This is your central portal for breaking news, the latest research and important updates from Dana-Farber Cancer Institute. Bookmark this page and check back often for updates.

Feature

‘We have to cure’ cancer, says CAR T pioneer Carl H. June, MD

April 18, 2019
Carl H. June , MD, is about to receive an award for his life’s work — it's not his first and it certainly won’t…
Meeting News

ASCO task force plans ‘new approaches’ to close rural cancer care gap

April 11, 2019
Patients with cancer who reside in rural areas routinely deal with logistical issues that affect their ability to receive treatment, often leading to…
Point/Counter

Is ibrutinib-based therapy the preferred initial treatment for all patients with CLL?

HemOnc Today, April 10, 2019
POINT CLL is the most common leukemia among adults. Standard treatment is combination chemoimmunotherapy with regimens such as chlorambucil plus…
Cover Story

Advances in chronic lymphocytic leukemia suggest progress is ‘visible on the horizon’

HemOnc Today, April 10, 2019
The transition from primarily chemotherapy-based approaches to targeted therapies revolutionized treatment of chronic lymphocytic leukemia, the most…
Meeting News

Reduced initial dose of cabozantinib may be feasible in advanced renal cell carcinoma

April 5, 2019
FORT WORTH, Texas — Patients with advanced renal cell carcinoma may be able to receive a lower starting dose of cabozantinib without…
Meeting News

Osimertinib plus intermittent selumetinib shows preliminary activity in EGFR-mutated lung cancer

April 2, 2019
ATLANTA — Osimertinib plus intermittent selumetinib demonstrated preliminary antitumor activity and acceptable toxicity in patients with…
In the Journals

Opioid-related hospitalizations uncommon, but slowly rising, among patients with cancer

March 28, 2019
Opioid-related hospitalizations among patients with cancer in the United States are rare and increasing at a low rate despite the opioid epidemic…

Immunotherapy likely to become standard for recurrent/metastatic head and neck cancers

March 22, 2019
The standard treatment for patients with recurrent or metastatic head and neck cancers is expected to change from chemotherapy to immunotherapy based…

Brachytherapy improves survival in advanced cervical cancer, but racial disparities remain

March 17, 2019
One study presented at Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer demonstrated the survival benefits of…

Niraparib extends time without symptoms for women with recurrent ovarian cancer

March 16, 2019
Niraparib maintenance therapy prolonged the time without symptoms or toxicity compared with placebo among women with recurrent ovarian cancer…
Meeting News

Challenges, opportunities remain in breast cancer survivorship care

March 13, 2019
MIAMI — Although significant progress has been made in breast cancer care, challenges and opportunities remain in cancer survivorship…
Meeting News

Pregnancy among young women with breast cancer requires tailored support, multidisciplinary approach

March 12, 2019
MIAMI — Pregnancy among young women with breast cancer requires a multidisciplinary team approach and modification of standard algorithms to…
Meeting News

First-line avelumab, axitinib benefit persists across advanced kidney cancer patient subgroups

February 19, 2019
SAN FRANCISCO — The combination of avelumab and axitinib induced longer PFS and higher objective response rates than sunitinib among previously…
Meeting News

Conservative management becomes most common approach for low-risk prostate cancer

February 12, 2019
Conservative prostate cancer management with active surveillance or watchful waiting increased significantly between 2010 and 2015 among men with…

Harvard professor to receive cancer drug development award

February 9, 2019
Geoffrey Shapiro , MD, PhD, will receive the TAT 2019 Honorary Award for cancer drug development. The award will be presented at TAT…
In the Journals Plus

Black men with low-risk prostate cancer have higher mortality rate

January 25, 2019
Black men diagnosed with low-risk prostate cancer may have more aggressive forms of the disease than nonblack men with the same diagnosis, according…

Dana-Farber Cancer Institute to study link between microbiome, colorectal cancer

January 25, 2019
The Dana-Farber Cancer Institute has received up to $25 million to begin a project that will aim to discover how certain microbes inside a…
Cover Story

Early collaboration with psycho-oncologists can make ‘meaningful difference’ in reducing suicide risk

HemOnc Today, January 25, 2019
Despite treatment advances and corresponding improvements in survival, suicide rates among those with cancer are alarmingly high — two times…
In the Journals Plus

Ibrutinib effective among patients with rare Bing-Neel syndrome

January 18, 2019
Ibrutinib induced rapid and durable responses among patients with Bing-Neel syndrome, a condition that affects only about 1% of patients with…

Dana-Farber Cancer Institute appoints executive vice president

January 13, 2019
James Terwilliger has been appointed executive vice president and chief operating officer at Dana-Farber Cancer Institute. His appointment will be…